Kyverna Therapeutics KYTX Institutional Ownership

Updated Oct 11, 2026

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) was reported as a holding by 120 institutional investors in 13F filings for the quarter ended June 30, 2026.

• Together they owned 61.06% of the outstanding stock in Q2 2026, up from 57.53% a quarter earlier.
• Total shares held in Kyverna Therapeutics rose 7.96% versus Q1 2026, while the number of holders rose 57.89% versus Q2 2025.
• Of the 120 holders of KYTX in Q2 2026, 69 added to their positions, 28 reduced their stakes and 23 left their positions unchanged.
• Combined, institutional investors held 37.59Mn shares of KYTX as of Q2 2026, up 2.77Mn from the prior quarter and up 14.91Mn from a year earlier.
• GordonMD Global Investments LP held the largest position in KYTX at 4.24Mn shares as of June 30, 2026, or 6.89% of shares outstanding.
• Among existing holders, the largest additions to Kyverna Therapeutics in Q2 2026 came from BlackRock, Inc. (+2.26Mn shares), State Street Corp (+843.93K shares), AIGH Capital Management LLC (+795.8K shares), Geode Capital Management, LLC (+625.6K shares) and Wells Fargo & Company (+258.61K shares).
• The biggest cuts to KYTX positions during Q2 2026 came from Balyasny Asset Management L.P. (-1.03Mn shares), Susquehanna International Group, LLP (-421.8K shares), T. Rowe Price Associates Inc (-369.26K shares), Millennium Management LLC (-365.73K shares) and D. E. Shaw & Co., Inc. (-252.24K shares).
• Business Quant data shows the 10 biggest positions in Kyverna Therapeutics as of Q2 2026 were held by GordonMD Global Investments LP (4.24Mn shares), Gilead Sciences, Inc. (4.13Mn shares), BlackRock, Inc. (3.13Mn shares), Bain Capital Life Sciences Investors, LLC (2.88Mn shares), AIGH Capital Management LLC (2.8Mn shares), Deerfield Management Company, L.P. (2Mn shares), Vanguard Capital Management LLC (1.9Mn shares), T. Rowe Price Associates Inc (1.19Mn shares), Geode Capital Management, LLC (1.05Mn shares) and Insight Holdings Group, LLC (989.05K shares).